TELA Bio Reports Increased Q1 Net Loss, Negative Equity, and High Cash Burn Amid Nasdaq Delisting Concerns

summarizeSummary

TELA Bio reported a larger net loss and increased cash burn in Q1 2026, leading to negative stockholders' equity, intensifying financial distress as the company navigates a Nasdaq delisting notice and plans for further share issuance.

check_boxKey Events

• Increased Net Loss

  Net loss for Q1 2026 increased to $12.3 million, up from $11.3 million in Q1 2025, reflecting continued operational challenges.

• Negative Stockholders' Equity

  Total stockholders' equity turned negative, reaching a deficit of $5.2 million as of March 31, 2026, a significant decline from $6.3 million in positive equity at year-end 2025.

• High Operating Cash Burn

  Cash used in operating activities rose to $11.2 million in Q1 2026, compared to $9.7 million in the prior year, indicating an accelerating cash burn rate.

• Modest Revenue Growth

  Revenue grew by a modest 3% to $19.1 million in Q1 2026 from $18.5 million in Q1 2025, primarily driven by international sales but offset by U.S. price mix headwinds.

auto_awesomeAnalysis

TELA Bio's first-quarter 2026 results reveal a worsening financial position, with the company reporting a net loss of $12.3 million, an increase from $11.3 million in the prior year. Critically, the company's total stockholders' equity has turned negative, reaching a deficit of $5.2 million, down from a positive $6.3 million at the end of 2025. Operating cash burn also intensified, with $11.2 million used in Q1 2026 compared to $9.7 million in Q1 2025. This financial deterioration occurs while the company is already facing a Nasdaq deficiency letter for failing to meet the minimum bid price requirement. The company also disclosed a board-approved proposal to increase its equity incentive plan by 3.5 million shares, subject to shareholder approval in June, indicating further potential dilution as it seeks to manage its liquidity and operational challenges.